drugset / Trial / NCT02259010

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

NCT02259010

Phase 1 Completed 24 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelBasic science

Summary

This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.

Timeline

Start
2014-10-22
Primary completion
2015-03-27
Completion
2016-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Alisertib Small molecule 30 mg Oral
Subject Alisertib Small molecule 50 mg Oral
Subject Itraconazole Small molecule 200 mg Oral

Indications